Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Drug Therapy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 140 Breast Neoplasms 93 Colorectal Neoplasms 69 Neoplasms 56 Lung Neoplasms 55 Stomach Neoplasms 48 Neoplasm Metastasis 45 Pancreatic Neoplasms 44 Rectal Neoplasms 40 Ovarian Neoplasms 39 Esophageal Squamous Cell Carcinoma 36 Esophageal Neoplasms 31 Squamous Cell Carcinoma of Head and Neck 29 Head and Neck Neoplasms 28 Leukemia, Myeloid, Acute 26 Small Cell Lung Carcinoma 22 Triple Negative Breast Neoplasms 21 Recurrence 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Nasopharyngeal Carcinoma 20 Colonic Neoplasms 20 Lymphoma 18 Glioblastoma 17 Fallopian Tube Neoplasms 17 Uterine Cervical Neoplasms 16 Prostatic Neoplasms 16 Lymphoma, Non-Hodgkin 16 Sarcoma 15 Melanoma 15 Leukemia 14

Interventions

Trastuzumab 3 pyrotinib 2 pertuzumab 2 Fulvestrant 2 tucatinib 1 palbociclib 1 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Docetaxel 1 Capecitabine 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡